Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-407: Carboplatin-taxane chemotherapy with or without pembrolizumab in first-line metastatic squamous NSCLC
2016-000229-38Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Pulmonary squamous cell carcinoma and Large Cell Lung Carcinoma (LCLC) comparing Pembrolizumab + carboplatin-taxane with Placebo + carboplatin-taxane (2 arms). Primary endpoint: Progression-free survival. Started Apr 2016; status: completed.
02
Drugs
03
Conditions
Pulmonary squamous cell carcinomaLarge Cell Lung Carcinoma (LCLC)
Beyond the preview
Go deeper on 2016-000229-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000229-38.